NEW YORK (GenomeWeb News) – Madrid-based Labec Pharma has entered a license agreement with Interleukin Genetics under which it will offer a genetic test for heart attack risk in Spain and Portugal, Interleukin Genetics said today.
Under the agreement, Labec Pharma will market the Heart Health tests, and Interleukin Genetics will process them in its lab in Waltham, Mass. Interleukin will receive royalties and milestone payments from Labec.
The companies also said that they plan to seek CE Mark certification for the test.
The test, which is sold in the US under the name Gensona, identifies variation in the IL-1 genes that are responsible for over-expression of inflammatory cytokines, which in certain individuals may be an indicator of a statistically significant risk for heart attack.
Heart disease and heart attacks are the second leading cause of death in Spain, with roughly 25,000 people dying from heart disease in the country each year, and in Portugal it accounts for around 5,000 deaths per year.